Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib ; volume:9 ; number:2 ; day:17 ; month:12 ; year:2021 ; pages:411-433 ; date:4.2022
Rheumatology and therapy ; 9, Heft 2 (17.12.2021), 411-433, 4.2022
- Creator
-
Dikranian, Ara
Gold, David
Bessette, Louis
Nash, Peter
Azevedo, Valderilio F.
Wang, Lisy
Woolcott, John
Shapiro, Andrea B.
Szumski, Annette
Fleishaker, Dona
Wollenhaupt, Jürgen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-021-00405-w
- URN
-
urn:nbn:de:101:1-2022061809233594128064
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dikranian, Ara
- Gold, David
- Bessette, Louis
- Nash, Peter
- Azevedo, Valderilio F.
- Wang, Lisy
- Woolcott, John
- Shapiro, Andrea B.
- Szumski, Annette
- Fleishaker, Dona
- Wollenhaupt, Jürgen
- SpringerLink (Online service)
Other Objects (12)
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?
Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage
Rheumatoide Arthritis: Kardiovaskuläre Komplikationen unter Tofacitinib
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?
Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage
Rheumatoide Arthritis: Kardiovaskuläre Komplikationen unter Tofacitinib
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?
Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage